TOIIW (The Oncology Institute) Long-Term Debt: $78.61 Mil (As of Mar. 2026)


TOIIW The Oncology Institute Inc TOIIW
56 GF Score
Price $0.06
! 6 Warning Signs
View Full Analysis

What is The Oncology Institute Long-Term Debt?

The Oncology Institute TOIIW 56 Long-Term Debt is $78.61 Mil as of Mar. 2026. GuruFocus rates TOIIW with a GF Score™ of 56/100. The stock has 6 warning signs investors should review.

The Oncology Institute's Long-Term Debt for the quarter that ended in Mar. 2026 was $78.61 Mil.

The Oncology Institute's quarterly Long-Term Debt increased from Sep. 2025 ($76.20 Mil) to Dec. 2025 ($77.40 Mil) and increased from Dec. 2025 ($77.40 Mil) to Mar. 2026 ($78.61 Mil).

The Oncology Institute's annual Long-Term Debt increased from Dec. 2023 ($86.83 Mil) to Dec. 2024 ($93.13 Mil) but then declined from Dec. 2024 ($93.13 Mil) to Dec. 2025 ($77.40 Mil).

The Oncology Institute  (NAS:TOIIW) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

The Oncology Institute Long-Term Debt Related Terms

The Oncology Institute Long-Term Debt Historical Data

* Premium members only.

The historical data trend for The Oncology Institute's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Oncology Institute Long-Term Debt Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 80.62 86.83 93.13 77.40

The Oncology Institute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.89 75.02 76.20 77.40 78.61
TOIIW
56GF Score
The Oncology Institute Inc TOIIW
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $78.61 Mil mean?
The Oncology Institute (TOIIW) has a Long-Term Debt of $78.61 Mil as of Mar. 2026.
Is The Oncology Institute's Long-Term Debt too high?
The Oncology Institute's current Long-Term Debt is $78.61 Mil. Overall, The Oncology Institute has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Long-Term Debt compare to CYH and SRTA?
The Oncology Institute's Long-Term Debt of $78.61 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. The Oncology Institute's current Long-Term Debt is $78.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Long-Term Debt of $78.61 Mil. The current Long-Term Debt is $78.61 Mil. The Oncology Institute's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Long-Term Debt is $78.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Oncology Institute Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for TOIIW

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price